薬物による肝損傷 第2部: 後期合併症と肝毒性モニタリング
Dorota M Kozielewicz1,2, Piotr Stalke3
1Department of Infectious Diseases and Hepatology, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Poland.
Clinical and experimental hepatology
|September 4, 2025
まとめ
薬物誘発性肝損傷 (DILI) は,線維症や自己免疫性肝炎を含む慢性肝疾患につながる可能性があります. DILIに関連する長期的な結果と死亡リスクは不明であり,さらなる調査が必要である.
科学分野:
- ヘパトロジー
- 毒理学について
- 免疫学
背景:
- 薬物誘発性肝損傷 (DILI) は,様々な臨床的症状と予後を示します.
- ほとんどのDILI症例は急性であるが,慢性肝病は薬物の停止後6〜12ヶ月以内に3. 4%〜39. 0%の症例で発生する.
- 慢性的なDILIに関連する長期的な罹患率と死亡率はよく定義されていません.
研究 の 目的:
- 薬物誘発性肝損傷 (DILI) の多形性を明らかにする.
- DILI の後に発生する 慢性肝疾患のスペクトルを見直す
- 阻害性胆道症候群などの特定のDILIの予後的な影響を強調する.
主な方法:
- DILIに関する既存のデータの文献レビューと統合.
- 薬物曝露後の慢性肝病の報告症例の分析
- DILIにおける長期的な影響と予後要因の検討
主要な成果:
- DILIは多形的な臨床画像を示し,結果は変動する.
- 慢性肝病は,繊維症,自己免疫性肝炎,肉脂肪症を含む,DILI後発症することがあります.
- 胆管阻害症候群は,肝不全や移植を必要とする,不良な予後に関連した希少だが深刻な合併症である.
- 免疫チェックポイント阻害剤は,T細胞浸透による硬化性胆炎を誘発する可能性があります.
結論:
- DILIの長期的後遺症は多様で,患者の罹病率と死亡率に大きな影響を与える可能性があります.
- 慢性肝疾患のリスクを軽減するために DILIの早期発見と管理は極めて重要です.
- 慢性的な影響を理解し,DILIの治療戦略を最適化するために,さらなる研究が必要である.
関連する概念動画
Acute Kidney Injury IV: Diagnostic Studies and Prevention
57
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
57
Esophageal Varices-II: Clinical Features and Management
133
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
133
Acute Kidney Injury III: Clinical Manifestations
86
Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
86
Nonlinear Pharmacokinetics: Overview
541
Nonlinear or dose-dependent pharmacokinetics is a phenomenon that occurs when the pharmacokinetic parameters of certain drugs deviate from linear pharmacokinetics at higher doses. These drugs do not follow the expected first-order kinetics, where the rate of drug elimination is directly proportional to the drug concentration. Instead, they exhibit a nonlinear relationship, which can be attributed to several factors.
Nonlinearity can arise due to the saturation of plasma protein-binding or...
Nonlinearity can arise due to the saturation of plasma protein-binding or...
541
Pharmacovigilance
981
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
981
Hepatic Drug Excretion: Influencing Factors
214
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
214


